Review
Allergy
Andrew W. Liu, Jacob E. Gillis, Tina L. Sumpter, Daniel H. Kaplan
Summary: The skin is populated by various immune cells and sensory neurons, and the interaction between the nervous and immune systems plays a crucial role in inflammatory skin diseases. Neurotransmitters secreted by nerve terminals mediate immune cell function, while immune factors derived from immune cells interact with neurons to induce itching. This review explores the effector functions of neurons on skin immune cells in mouse models of atopic and contact dermatitis, and discusses the contribution of specific neuronal subsets and immune factors to itch induction and inflammation. The findings also shed light on treatment strategies and the relationship between scratching and dermatitis.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Lai-San Wong, Yu-Ta Yen, Chih-Hung Lee
Summary: Atopic dermatitis is a prototypic inflammatory disease characterized by intense itching, with multifactorial pathophysiology involving environmental factors, genetic susceptibility, skin barrier function, and immune responses. Recent research has shown that pruritogens not only trigger itch but also interact with immune cells and act as inflammatory mediators, worsening the severity of atopic dermatitis. Targeted therapies for atopic dermatitis focus on the interaction between pruritogens and inflammatory molecules.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Franz J. Legat
Summary: Atopic dermatitis is a common inflammatory skin disease affecting up to 20% of children and 10% of adults in higher income countries, with chronic pruritus as a major symptom causing significant impact on quality of life. New systemic and topical treatments targeting specific cytokines and receptors have ushered in a new era in atopic dermatitis and pruritus therapy.
FRONTIERS IN MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Yoshie Umehara, Chanisa Kiatsurayanon, Juan Valentin Trujillo-Paez, Panjit Chieosilapatham, Ge Peng, Hainan Yue, Hai Le Thanh Nguyen, Pu Song, Ko Okumura, Hideoki Ogawa, Francois Niyonsaba
Summary: Itch or pruritus is a hallmark of atopic dermatitis and is believed to be a signal of danger from various environmental factors or physiological abnormalities. While histamine is a well-known substance inducing itch, H-1-antihistamines may not be fully effective against intractable itch in patients with atopic dermatitis. Treatment of the underlying conditions that cause itch is necessary to improve the quality of life of patients with atopic dermatitis.
Article
Medicine, General & Internal
Kjell Lussmann, Kerry Montgomery, Andrew Thompson, Uwe Gieler, Christoph Zick, Joerg Kupfer, Christina Schut
Summary: Itch intensity is positively correlated with itch catastrophizing, while mindfulness is negatively correlated with itch catastrophizing. Increasing acting with awareness may buffer itch catastrophizing and lead to lower itch intensity in patients with AD.
FRONTIERS IN MEDICINE
(2021)
Review
Allergy
Raj Chovatiya, Amy S. Paller
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options. Recent studies have shown that both topical and systemic Janus kinase (JAK) inhibitors hold promise in treating AD, with further research needed to fully understand their efficacy and safety.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Niuniu Yang, Haifeng Shao, Jialin Deng, Yan Yang, Zongxiang Tang, Guanyi Wu, Yanqing Liu
Summary: Chronic itch is a prominent feature of atopic dermatitis (AD), and antihistamine treatment is often ineffective. This study focused on the MrgprA3-TRPA1 itch pathway and explored the potential of dictamnine, a component of Cortex Dictamni, in treating AD-induced chronic itch. The results showed that dictamnine effectively reduced itch, inflammation, and expression of MrgprA3 and TRPA1 in a mouse model of AD. It also inhibited the excitability of itch-sensing neurons. These findings suggest that dictamnine may have therapeutic potential for AD treatment.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Dermatology
Amy S. Paller, Jin-Shei Lai, Kathryn Jackson, Stephanie M. Rangel, Cindy Nowinski, Jonathan Silverberg, Vitali Ustsinovich, David Cella
Summary: This study aimed to develop and validate a comprehensive assessment tool for itch symptoms and impact in children. The resulting questionnaire showed good validity, discriminating ability, and responsiveness to change. It provides an alternative tool to assess the quality of life specifically affected by itch.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Letter
Engineering, Environmental
Jordan Zeldin, Tan T. Tran, Manoj Yadav, Prem Prashant Chaudhary, Brandon N. D'Souza, Grace Ratley, Sundar Ganesan, Ian A. Myles
Summary: Compared to rhinitis and asthma, environmental exposure research for atopic dermatitis (AD) is not well established. An analysis of U.S. EPA databases revealed that isocyanates are strongly associated with AD. Further research identified antimony compounds as another top associated pollutant in regions with low levels of diisocyanate pollution. These findings suggest a causal relationship between compounds associated with AD, inhibition of commensal lipid production, and activation of TRPA1.
ENVIRONMENTAL SCIENCE & TECHNOLOGY LETTERS
(2023)
Review
Medicine, General & Internal
Catharina Sagita Moniaga, Mitsutoshi Tominaga, Kenji Takamori
Summary: Recent evidence on type 2 inflammation-associated itch in atopic dermatitis has been reported, highlighting the importance of neuroimmune interactions in research. Understanding bidirectional neuroimmune interactions is crucial in gaining insights into the pathogenesis of itch and its treatment. Improved management and treatment options for itch in atopic dermatitis are being explored through novel and targeted biologic agents in advanced clinical trials.
Article
Dermatology
Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, Ignasi Figueras-Nart, Laurent Misery, Nithi Tangsirisap, Lara Spina, Na Lu, Sussanne Grond, Kilian Eyerich
Summary: Baricitinib treatment leads to rapid and sustained improvements in clinical signs of inflammation, especially itch and excoriation, in patients with moderate-to-severe atopic dermatitis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Allergy
Mitsutoshi Tominaga, Kenji Takamori
Summary: Atopic dermatitis is a skin disorder characterized by dryness and dysfunction of the skin barrier, leading to inflammation and chronic itch. The itch sensation is sensitized by the increase in intraepidermal nerve fibers and the secretion of IL-33 by keratinocytes. The breakdown of the skin barrier allows allergens to enter the epidermis, triggering type 2 inflammatory responses and worsening itch. Controlling itch is crucial for the treatment of atopic dermatitis.
ALLERGOLOGY INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Zhiping Lu, Song Xiao, Weiwei Chen, Renkai Zhu, Hua Yang, Martin Steinhoff, Yanqing Li, Wenke Cheng, Xinrong Yan, Lianlian Li, Shanghai Xue, Ciara Larkin, Wenhao Zhang, Qianqian Fan, Ruizhen Wang, Jiafu Wang, Jianghui Meng
Summary: IL-20 expression in skin is upregulated in atopic dermatitis, and it triggers calcium influx in keratinocytes and sensory neurons, leading to release of AD-related molecules and transcription of itch-related genes. In a murine model, co-injection of IL-20 and IL-13 elicits significant itch-like behavior.
Article
Dermatology
Gabrielle Schwartzman, Donald Lei, Muhammad Yousaf, Sherief R. Janmohamed, Paras P. Vakharia, Rishi Chopra, Rajeev Chavda, Sylvie Gabriel, Kevin R. Patel, Vivek Singam, Robert Kantor, Derek Y. Hsu, Jonathan I. Silverberg
Summary: The study found that PGH scores are valid and reliable for assessing health-related quality of life in adult atopic dermatitis.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Review
Cell Biology
Catharina Sagita Moniaga, Mitsutoshi Tominaga, Kenji Takamori
Summary: Skin and gut microbiota play important roles in the pathogenesis of atopic dermatitis (AD). The diversity of microbiota is altered in AD, and this alteration is correlated with disease severity, especially in the lesional skin. Recent evidence suggests that microbiota might affect itch in AD through gut-skin-brain interactions. Microbial metabolites, proinflammatory cytokines, and impaired immune response contribute to histamine-independent itch, disruption of the epidermal barrier, and central sensitization of itch mechanisms. Probiotics have shown positive effects in alleviating itch in AD, indicating potential novel strategies for managing itchy skin in AD patients.
Editorial Material
Dermatology
Brett C. Neill, Vivek Singam, Isadore S. Tarantino, Lindsey B. Bauer, Thomas L. H. Hocker
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Letter
Dermatology
Jonathan I. Silverberg, Stephanie M. Rangel, Anjani Sheth, Alli Blumstein, Amy S. Paller
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Editorial Material
Allergy
Erin M. Warshaw, Michelle Xiong, Joel G. DeKoven, James S. Taylor, Donald V. Belsito, Margo J. Reeder, Brandon L. Adler, Melanie D. Pratt, Amber R. Atwater, Howard I. Maibach, Jonathan I. Silverberg, JiaDe Yu, Nina Botto, Joseph F. Fowler, Marie-Claude Houle, Christen M. Mowad, Cory A. Dunnick, Vincent A. DeLeo
CONTACT DERMATITIS
(2023)
Article
Dermatology
Trisha Kaundinya, Uros Rakita, Jonathan I. Silverberg
Summary: This study examined the prevalence and associations of sexual dysfunction (SD) in adults with atopic dermatitis (AD). The results showed that 19.35% of patients reported SD, which was associated with marital status, age, and severity of AD.
Review
Allergy
Juan Jose Yepes-Nunez, Gordon H. Guyatt, Luis Guillermo Gomez-Escobar, Lucia C. Perez-Herrera, Alexandro W. L. Chu, Renata Ceccaci, Ana Sofia Acosta-Madiedo, Aaron Wen, Sergio Moreno-Lopez, Margaret MacDonald, Monica Barrios, Xiajing Chu, Nazmul Islam, Ya Gao, Melanie M. Wong, Rachel Couban, Elizabeth Garcia, Edgardo Chapman, Paul Oykhman, Lina Chen, Tonya Winders, Rachel Netahe Asiniwasis, Mark Boguniewicz, Anna De Benedetto, Kathy Ellison, Winfred T. Frazier, Matthew Greenhawt, Joey Huynh, Elaine Kim, Jennifer LeBovidge, Mary Laura Lind, Peter Lio, Stephen A. Martin, Monica O'Brien, Peck Y. Ong, Jonathan I. Silverberg, Jonathan Spergel, Julie Wang, Kathryn E. Wheeler, Lynda Schneider, Derek K. Chu
Summary: This article summarizes the evidence regarding the benefits and harms of allergen immunotherapy (AIT) for atopic dermatitis (AD). The findings indicate that subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) can significantly improve the severity and quality of life of AD patients, but they may also increase adverse events. Therefore, a multidisciplinary and shared decision-making approach should be adopted for optimal management of AD.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Allergy
Emma Guttman-Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Kim A. Papp, Amy S. Paller, Stephan Weidinger, H. Chih-ho Hong, Barbara Hendrickson, Deanne Dilley, Allan R. Tenorio, Barry Ladizinski, Alvina D. Chu, John Liu, Alan D. Irvine
Summary: This study evaluated the safety of upadacitinib in patients with moderate-to-severe atopic dermatitis. The results showed that upadacitinib was well tolerated by both adults and adolescents. The frequency of adverse events was higher in the 30 mg group compared to the 15 mg group, but the rates of serious adverse events were similar in both groups. Acne was the most commonly reported adverse event.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Dermatology
Jonathan I. Silverberg, Eric L. Simpson, Jacob Pontoppidan Thyssen, Thomas Werfel, Tracy E. Cardillo, Stephanie Colvin, Evangeline Pierce, Yun-Fei Chen, Sherry Chen, Lawrence Eichenfield
Summary: Baricitinib combined with topical corticosteroids (TCS) has shown sustained efficacy in treating adults with moderate-to-severe atopic dermatitis (AD) over a 68-week period.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Jonathan I. Silverberg, Robert Bissonnette, Leon Kircik, Dedee F. Murrell, Andrew Selfridge, Kris Liu, Gurpreet Ahluwalia, Emma Guttman-Yassky
Summary: This study evaluated the efficacy and safety of etrasimod monotherapy in the treatment of moderate-to-severe atopic dermatitis. The results showed that etrasimod 2 mg demonstrated efficacy on clinician- and patient-assessed measures, and both 1 mg and 2 mg doses were well tolerated, supporting further clinical investigation in atopic dermatitis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Stephanie M. Rangel, Theodore Kim, Anjani Sheth, Alli Blumstein, Jin-Shei Lai, David Cella, Amy S. Paller, Jonathan Silverberg
Summary: This study aims to determine the prevalence of fatigue in AD patients, and whether AD severity, demographics and comorbidities are associated with increased fatigue in children. The results showed that many children with AD had no or mild fatigue, but fatigue was associated with AD severity, history of allergic diseases, and family income.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Dermatology
Keon Andre Maleki-Yazdi, Anja Fog Heen, Irene X. Zhao, Gordon H. Guyatt, Erica A. Suzumura, Nima Makhdami, Lina Chen, Tonya Winders, Kathryn E. Wheeler, Julie Wang, Jonathan Spergel, Jonathan I. Silverberg, Peck Y. Ong, Monica O'Brien, Stephen A. Martin, Peter A. Lio, Mary Laura Lind, Jennifer LeBovidge, Elaine Kim, Joey Huynh, Matthew Greenhawt, Winfred T. Frazier, Kathy Ellison, Korey Capozza, Anna De Benedetto, Mark Boguniewicz, Wendy Smith Begolka, Rachel Netahe Asiniwasis, Lynda C. Schneider, Derek K. Chu
Summary: This article systematically summarizes patient values and preferences in the management of atopic dermatitis (AD). Six key themes have been identified that may inform optimal clinical care, practice guidelines, and future research.
Article
Dermatology
Margo J. Reeder, Erin Warshaw, Srikanth Aravamuthan, Donald V. Belsito, Johannes Geier, Mark Wilkinson, Amber Reck Atwater, Ian R. White, Jonathan I. Silverberg, James S. Taylor, Joseph F. Fowler Jr, Howard I. Maibach, Joel G. DeKoven, Timo Buhl, Nina Botto, Ana Maria Gimenez-Arnau, Rosella Gallo, Christen Mowad, Claudia C. V. Lang, Vincent A. DeLeo, Graham Johnston, Melanie D. Pratt, Knut Brockow, Brandon L. Adler, Marie-Claude Houle, Heinrich Dickel, Marie Louise A. Schuttelaar, JiaDe Yu, Radoslaw Spiewak, Cory Dunnick, Francesca Larese Filon, Skaidra Valiukeviciene, Wolfgang Uter
Summary: From 2017 to 2018, the number of cases of isothiazolinone allergy decreased in Europe while it continued to increase in North America. This may be attributed to earlier and more stringent government regulation of isothiazolinones in Europe.
Article
Dermatology
Amy S. Paller, Jonathan I. Silverberg, Michael J. Cork, Emma Guttman-Yassky, Benjamin Lockshin, Alan D. Irvine, Moon Bum Kim, Kenji Kabashima, Zhen Chen, Yufang Lu, Ashish Bansal, Ana B. Rossi, Arsalan Shabbir
Summary: This study assessed the efficacy and safety of dupilumab in patients with severe erythrodermic atopic dermatitis (AD). The results showed that dupilumab significantly improved AD signs and symptoms, including affected body surface area, Eczema Area and Severity Index (EASI) score, and Pruritus Numerical Rating Scale (PP-NRS) score. The treatment also led to reductions in serum biomarker levels.
Article
Dermatology
Jonathan I. Silverberg, Charles W. Lynde, Katrina Abuabara, Cataldo Patruno, Anna de Benedetto, Haixin Zhang, Ryan B. Thomas, Gaelle Bego-Le-Bagousse, Faisal A. Khokhar, Jignesh Vakil, Ainara Rodriguez Marco, Noah A. Levit
Summary: This study reported the efficacy and safety of dupilumab in patients aged ≥ 60 years with moderate-to-severe atopic dermatitis. The results showed significant improvements in skin lesions, symptoms, biomarkers, and quality of life in dupilumab-treated patients at week 16. The safety profile of dupilumab in patients aged ≥ 60 years was consistent with previous findings.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2023)
Article
Dermatology
Shanthi Narla, Candrice R. Heath, Andrew Alexis, Jonathan I. Silverberg
Summary: Significant racial/ethnic disparities in dermatologic care and their subsequent impact on dermatologic conditions were reported. Key contributing factors include socioeconomic factors, gaps in educational exposure, and underrepresentation of minority groups in the dermatologic workforce. The American Academy of Dermatology (AAD) announced a three-year plan to promote diversity, equity, and inclusion in dermatology. To reduce disparities, every dermatologist should receive adequate education in diseases, treatments, health equity, and culturally sensitive care. A diverse dermatologic workforce can improve cross-cultural understanding and treatment approaches for different racial/ethnic populations, while acknowledging and educating on the health impacts of racism is essential for the healthcare community.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
Review
Dermatology
Alex M. Rokni, Marissa Ayasse, Adnan Ahmed, Lauren Guggina, Robert W. Kantor, Jonathan Silverberg
Summary: This study systematically reviewed the relationship between autoimmune blistering disease (AIBD) and cardiovascular disease (CVD) and its risk factors. The findings showed that AIBD was associated with diabetes, hypertension, dyslipidemia, and heart failure, but not with obesity, stroke, angina, heart attack, or arrhythmia. The study also found that treatment for AIBD could result in CVD-related adverse events.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)